logo

For the Inventor, By the Inventor

Tokyo, Japan

Fumiyoshi Ishikawa

This inventor holds 5 USPTO granted patents. Top assignee: Daiichi Seiyaku Co., Ltd.. Active years: 1979-1986.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Fumiyoshi Ishikawa. Retrieved from https://idiyas.com/inventor/fumiyoshi-ishikawa

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 5

% Patents Active = 100.0

Average Co-Inventor Count = 2.1

ph-index = 4

Forward Citations = 42(Granted Patents)


Location History:

  • Funabashi, JP (1979)
  • Minamifunabori, JP (1981)
  • Tokyo, JP (1979 - 1986)

Company Filing History:

goldMedal5 out of 70 
 
Daiichi Seiyaku Co., Ltd.
 patents

Years Active: 1979-1986

Loading Chart...
5 patents (USPTO):Explore Patents
1. 4610987 - Imidazoquinazolin-2-one compounds (1986-09-09),
2. 4596806 - 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one having (1986-06-24),
3. 4284773 - 1,2,3,5-Tetrahydroimidazothienopyrimidin-2-ones (1981-08-18),
4. 4138491 - Method for treating diabetes (1979-02-06),
5. 4136188 - Treatment of diabetes with 2-substituted-1,3-diazacyclic compounds (1979-01-23),

Title: Fumiyoshi Ishikawa: Innovator in Pharmaceutical Compounds

Introduction

Fumiyoshi Ishikawa is a prominent inventor based in Tokyo, Japan. He has made significant contributions to the field of pharmaceuticals, particularly in the development of compounds that have therapeutic applications. With a total of 5 patents to his name, Ishikawa's work is recognized for its innovative approach to addressing medical challenges.

Latest Patents

Ishikawa's latest patents include the development of imidazoquinazolin-2-one compounds. These compounds exhibit platelet aggregation inhibitory activity, which is crucial for treating and preventing intravascular thromboembolism and temporary ischemia. Notably, these compounds are characterized by high water-solubility and minimal impact on the circulatory system. Another significant patent involves a specific compound, 7-piperidino-1,2,3,5-tetrahydroimidazo[2,1-b]-quinazolin-2-one, which also demonstrates platelet aggregation inhibitory activity and shares similar beneficial properties.

Career Highlights

Fumiyoshi Ishikawa is currently associated with Daiichi Seiyaku Co., Ltd., a leading pharmaceutical company. His work at the company has been instrumental in advancing research and development in the field of medicinal chemistry. His innovative contributions have positioned him as a key figure in the industry.

Collaborations

Ishikawa has collaborated with notable colleagues, including Akira Kosasayama and Yoshifumi Watanabe. These partnerships have fostered a collaborative environment that enhances the research and development process.

Conclusion

Fumiyoshi Ishikawa's contributions to pharmaceutical innovations highlight his expertise and commitment to improving medical treatments. His patents reflect a dedication to advancing healthcare solutions, making him a significant figure in the field of medicinal chemistry.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…